gross profit bridgeinconsistent2026-06-30
Withheld: cost revenue could not be reconciled with the rest of this filer’s statement.
Revenue
$17.00K
Fiscal year ended 2026-06-30Operating income
-$1.84M
Fiscal year ended 2026-06-30Free cash flow
Unavailable
Fiscal year ended 2026-06-30Aspira Women's Health Inc. (AWHL) reported revenue of $17.00K and net income of -$2.42M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Aspira Women's Health Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under In Vitro & In Vivo Diagnostic Substances.
Income
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $17.00K | $32.00K | $2.23M | $89.00K | $169.00K | $0 | $2.35M | $2.26M | $2.42M | $2.15M |
| Cost of revenue | Unavailable | Unavailable | $790.00K | Unavailable | Unavailable | $719.00K | $860.00K | $902.00K | $1.00M | $939.00K |
| Gross profit | Unavailable | Unavailable | $1.44M | Unavailable | Unavailable | $1.56M | $1.49M | $1.36M | $1.42M | $1.21M |
| Operating income | -$1.84M | -$2.20M | -$1.28M | -$1.58M | -$1.81M | -$3.24M | -$3.43M | -$3.74M | -$4.39M | -$4.71M |
| Net income | -$2.42M | $676.00K | -$3.37M | -$4.89M | -$2.67M | -$1.85M | -$1.39M | -$3.55M | -$3.53M | -$4.63M |
| Research & development | $692.00K | $1.23M | $462.00K | $739.00K | $704.00K | $973.00K | $500.00K | $908.00K | $952.00K | $906.00K |
| Weighted-average diluted shares | shares 44.25M | shares 45.77M | Unavailable | shares 36.39M | shares 35.56M | shares 21.59M | Unavailable | shares 15.41M | shares 12.52M | shares 11.85M |
| Pretax income | Unavailable | $676.00K | Unavailable | Unavailable | Unavailable | -$1.85M | Unavailable | Unavailable | Unavailable | Unavailable |
| Income tax expense | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Diluted EPS | $-0.05 | $-0.05 | Unavailable | $-0.13 | $-0.07 | $-0.09 | Unavailable | $-0.23 | $-0.28 | $-0.39 |
| Selling, general & administrative | $2.27M | $2.05M | $2.26M | $2.22M | $2.64M | $3.83M | $4.42M | $4.19M | $4.86M | $5.02M |
| General & administrative | $1.71M | $1.50M | $1.72M | $1.54M | $1.96M | $2.74M | $2.44M | $2.05M | $2.72M | $3.13M |
| Selling & marketing | $567.00K | $543.00K | $538.00K | $683.00K | $679.00K | $1.09M | $1.98M | $2.14M | $2.14M | $1.89M |
Balance
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $477.00K | $1.34M | $1.76M | $3.81M | $1.54M | $3.31M | $1.77M | $2.13M | $962.00K | $3.41M |
| Total assets | $4.44M | $5.09M | $5.46M | $7.30M | $4.93M | $6.72M | $5.49M | $4.76M | $5.49M | $7.16M |
| Current assets | $2.80M | $3.78M | $4.06M | $5.82M | $3.69M | $5.39M | $4.18M | $4.11M | $3.25M | $6.12M |
| Total liabilities | $11.69M | $11.30M | $12.39M | $11.64M | $7.62M | $6.78M | $8.05M | $7.28M | $7.67M | $8.53M |
| Current liabilities | $5.34M | $5.60M | $3.46M | $4.20M | $4.10M | $3.79M | $5.47M | $5.47M | $5.46M | $5.29M |
| Total equity incl. NCI | -$7.26M | -$6.21M | -$6.93M | -$4.34M | -$2.68M | -$60.00K | -$2.56M | -$2.52M | -$3.71M | -$1.36M |
| Temporary (mezzanine) equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Inventory | $231.00K | $292.00K | $256.00K | $282.00K | $273.00K | $260.00K | $326.00K | $290.00K | $226.00K | $236.00K |
| Accounts receivable | $1.48M | $1.42M | $1.21M | $1.32M | $1.28M | $1.10M | $990.00K | $1.25M | $1.44M | $1.53M |
| Goodwill | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Long-term debt | $961.00K | $980.00K | $1.04M | $1.10M | $1.16M | $1.22M | $1.28M | $1.33M | $1.26M | $1.35M |
| Accounts payable | $2.75M | $1.97M | $1.24M | $1.81M | $1.74M | $1.45M | $2.17M | $2.55M | $1.94M | $1.64M |
Cash flow
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.01M | -$359.00K | -$1.98M | -$212.00K | -$1.73M | -$3.10M | -$1.02M | -$2.92M | -$3.74M | -$4.43M |
| Capital expenditures | Unavailable | Unavailable | $8.00K | Unavailable | Unavailable | Unavailable | $0 | $2.00K | $15.00K | $20.00K |
| Investing cash flow | Unavailable | Unavailable | -$8.00K | Unavailable | Unavailable | Unavailable | $0 | -$2.00K | -$15.00K | -$20.00K |
| Financing cash flow | $1.29M | -$52.00K | -$65.00K | $2.87M | -$33.00K | $4.64M | $657.00K | $4.09M | $1.04M | $5.27M |
| Net change in cash | -$867.00K | -$411.00K | -$2.05M | $2.26M | -$1.77M | $1.54M | -$364.00K | $1.17M | -$2.71M | $818.00K |
| Stock-based compensation | $19.00K | $42.00K | $376.00K | $36.00K | $16.00K | $103.00K | $630.00K | $380.00K | $122.00K | $362.00K |
| Common dividends paid | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Common share repurchases | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Depreciation & amortization | $40.00K | $40.00K | $38.00K | $50.00K | $11.00K | $13.00K | $14.00K | $23.00K | $26.00K | $29.00K |
Derived
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | Unavailable | Unavailable | -$1.99M | Unavailable | Unavailable | Unavailable | -$1.02M | -$2.92M | -$3.76M | -$4.45M |
| Gross margin | Unavailable | Unavailable | 64.5% | Unavailable | Unavailable | Unavailable | 63.4% | 60.0% | 58.6% | 56.4% |
| Operating margin | -10794.1% | -6884.4% | -57.6% | -1774.2% | -1071.0% | Unavailable | -146.1% | -165.9% | -181.3% | -218.8% |
| FCF margin | Unavailable | Unavailable | -89.3% | Unavailable | Unavailable | Unavailable | -43.5% | -129.5% | -155.0% | -206.7% |
| SBC / revenue | 111.8% | 131.2% | 16.9% | 40.4% | 9.5% | Unavailable | 26.8% | 16.8% | 5.0% | 16.8% |
| Current ratio | 0.52x | 0.68x | 1.17x | 1.39x | 0.90x | 1.42x | 0.76x | 0.75x | 0.60x | 1.16x |
| Revenue YoY growth | -89.9% | Unavailable | -5.2% | -96.1% | -93.0% | -100.0% | 10.3% | 1.8% | -2.7% | -7.0% |
| Net margin | -14235.3% | Unavailable | -151.2% | -5496.6% | -1577.5% | Unavailable | -59.1% | -157.2% | Unavailable | Unavailable |
| R&D / revenue | 4070.6% | 3831.2% | 20.7% | 830.3% | 416.6% | Unavailable | 21.3% | 40.2% | 39.3% | 42.1% |
| CapEx / revenue | Unavailable | Unavailable | 0.4% | Unavailable | Unavailable | Unavailable | 0.0% | 0.1% | 0.6% | 0.9% |
| Long-term debt / equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open AWHL in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-04-01View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-19View SEC filing
Reconciliation checks needing review
8 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.
gross profit bridgeinconsistent2026-03-31
Withheld: cost revenue could not be reconciled with the rest of this filer’s statement.
gross profit bridgeinconsistent2025-09-30
Withheld: cost revenue could not be reconciled with the rest of this filer’s statement.
gross profit bridgeinconsistent2025-06-30
Withheld: cost revenue could not be reconciled with the rest of this filer’s statement.
gross profit bridgereview2025-03-31
Difference 2279000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.
balance equationreview2024-06-30
Difference 1530000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.
cash flow reconciliationreview2023-09-30
Operating, investing and financing flows differ from the reported change in cash by 6642000, beyond tolerance 1000000.
cash flow reconciliationreview2023-06-30
Operating, investing and financing flows differ from the reported change in cash by 6834000, beyond tolerance 1000000.